Assessment of neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil in patients with oral cavity cancer
Abstract Background Chemotherapy with docetaxel, cisplatin, and fluorouracil (TPF) has been studied in patients with head and neck cancer. Its impact on patients with oral cavity cancer was not specified. Methods We consecutively reviewed medical files of patients with untreated oral cavity cancer w...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-02-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.5075 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850268747614388224 |
|---|---|
| author | Jin Ye Fu Xiu Hui Yue Min Jun Dong Jiang Li Chen Ping Zhang |
| author_facet | Jin Ye Fu Xiu Hui Yue Min Jun Dong Jiang Li Chen Ping Zhang |
| author_sort | Jin Ye Fu |
| collection | DOAJ |
| description | Abstract Background Chemotherapy with docetaxel, cisplatin, and fluorouracil (TPF) has been studied in patients with head and neck cancer. Its impact on patients with oral cavity cancer was not specified. Methods We consecutively reviewed medical files of patients with untreated oral cavity cancer who received neoadjuvant TPF chemotherapy in our department from January 2017 to April 2020. Outcomes included the objective response to TPF chemotherapy, factors associated with the response, and progression and survival in different response groups. Results A total of 167 patients were included, with half of stage IV disease. Complete or partial response was observed in 51 patients. A total of 91 patients had stable disease, and 25 patients had progressive disease. The response was not associated with age, sex, anatomic subsite, and the tumor's T stage. It was related with N stage (p < 0.001) and clinical stage (p = 0.004). Most patients with bulky nodes or nodes with obvious necrosis showed low response or even progressed after neoadjuvant TPF chemotherapy. The planned surgery was conducted in 159 patients. Disease relapse mostly occurred in 2 years after treatment. The 2‐year overall survival and the progression‐free survival were 89.0% and 85.2% for patients with complete or partial response, 62.4% and 55.6% for patients with stable disease, and 12.5% and 4.2% for patients with progressive disease, respectively. Conclusions The response of neoadjuvant TPF chemotherapy in patients with oral cavity cancer is related to disease stage, especially the nodal stage. Patients with complete or partial response developed less progression events and better survival. |
| format | Article |
| id | doaj-art-684d256ac22e48d2bcd79ac12e661025 |
| institution | OA Journals |
| issn | 2045-7634 |
| language | English |
| publishDate | 2023-02-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj-art-684d256ac22e48d2bcd79ac12e6610252025-08-20T01:53:22ZengWileyCancer Medicine2045-76342023-02-011232417242610.1002/cam4.5075Assessment of neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil in patients with oral cavity cancerJin Ye Fu0Xiu Hui Yue1Min Jun Dong2Jiang Li3Chen Ping Zhang4Department of Oral & Maxillofacial – Head & Neck Oncology, Shanghai Ninth People's Hospital College of Stomatology, Shanghai Jiao Tong University School of Medicine Shanghai ChinaDepartment of Radiology Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine Shanghai ChinaDepartment of Radiology Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine Shanghai ChinaNational Clinical Research Center for Oral Diseases & National Center for Stomatology Shanghai ChinaDepartment of Oral & Maxillofacial – Head & Neck Oncology, Shanghai Ninth People's Hospital College of Stomatology, Shanghai Jiao Tong University School of Medicine Shanghai ChinaAbstract Background Chemotherapy with docetaxel, cisplatin, and fluorouracil (TPF) has been studied in patients with head and neck cancer. Its impact on patients with oral cavity cancer was not specified. Methods We consecutively reviewed medical files of patients with untreated oral cavity cancer who received neoadjuvant TPF chemotherapy in our department from January 2017 to April 2020. Outcomes included the objective response to TPF chemotherapy, factors associated with the response, and progression and survival in different response groups. Results A total of 167 patients were included, with half of stage IV disease. Complete or partial response was observed in 51 patients. A total of 91 patients had stable disease, and 25 patients had progressive disease. The response was not associated with age, sex, anatomic subsite, and the tumor's T stage. It was related with N stage (p < 0.001) and clinical stage (p = 0.004). Most patients with bulky nodes or nodes with obvious necrosis showed low response or even progressed after neoadjuvant TPF chemotherapy. The planned surgery was conducted in 159 patients. Disease relapse mostly occurred in 2 years after treatment. The 2‐year overall survival and the progression‐free survival were 89.0% and 85.2% for patients with complete or partial response, 62.4% and 55.6% for patients with stable disease, and 12.5% and 4.2% for patients with progressive disease, respectively. Conclusions The response of neoadjuvant TPF chemotherapy in patients with oral cavity cancer is related to disease stage, especially the nodal stage. Patients with complete or partial response developed less progression events and better survival.https://doi.org/10.1002/cam4.5075neoadjuvant chemotherapyoral cavity cancerprogressionresponse ratesurvivalTPF regimen |
| spellingShingle | Jin Ye Fu Xiu Hui Yue Min Jun Dong Jiang Li Chen Ping Zhang Assessment of neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil in patients with oral cavity cancer Cancer Medicine neoadjuvant chemotherapy oral cavity cancer progression response rate survival TPF regimen |
| title | Assessment of neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil in patients with oral cavity cancer |
| title_full | Assessment of neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil in patients with oral cavity cancer |
| title_fullStr | Assessment of neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil in patients with oral cavity cancer |
| title_full_unstemmed | Assessment of neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil in patients with oral cavity cancer |
| title_short | Assessment of neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil in patients with oral cavity cancer |
| title_sort | assessment of neoadjuvant chemotherapy with docetaxel cisplatin and fluorouracil in patients with oral cavity cancer |
| topic | neoadjuvant chemotherapy oral cavity cancer progression response rate survival TPF regimen |
| url | https://doi.org/10.1002/cam4.5075 |
| work_keys_str_mv | AT jinyefu assessmentofneoadjuvantchemotherapywithdocetaxelcisplatinandfluorouracilinpatientswithoralcavitycancer AT xiuhuiyue assessmentofneoadjuvantchemotherapywithdocetaxelcisplatinandfluorouracilinpatientswithoralcavitycancer AT minjundong assessmentofneoadjuvantchemotherapywithdocetaxelcisplatinandfluorouracilinpatientswithoralcavitycancer AT jiangli assessmentofneoadjuvantchemotherapywithdocetaxelcisplatinandfluorouracilinpatientswithoralcavitycancer AT chenpingzhang assessmentofneoadjuvantchemotherapywithdocetaxelcisplatinandfluorouracilinpatientswithoralcavitycancer |